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Cardiovascular (CV) toxicity is a potential short- or long-term complication of various anticancer therapies. Some drugs,
such as anthracyclines or other biological agents, have been implicated in causing potentially irreversible clinically
important cardiac dysfunction. Although targeted therapies are considered less toxic and better tolerated by patients
compared with classic chemotherapy agents, rare but serious complications have been described, and longer follow-
up is needed to determine the exact proﬁle and outcomes of related cardiac side-effects. Some of these side-effects
are irreversible, leading to progressive CV disease, and some others induce reversible dysfunction with no long-term
cardiac damage to the patient. Assessment of the prevalence, type and severity of cardiac toxicity caused by various
cancer treatments is a breakthrough topic for patient management. Guidelines for preventing, monitoring and treating
cardiac side-effects are a major medical need. Efforts are needed to promote strategies for cardiac risk prevention,
detection and management, avoiding unintended consequences that can impede development, regulatory approval
and patient access to novel therapy. These new ESMO Clinical Practice Guidelines are the result of a multidisciplinary
cardio-oncology review of current evidence with the ultimate goal of providing strict criteria-based recommendations on
CV risk prevention, assessment, monitoring and management during anticancer treatment.
introduction
The rationale for Cardiology–Oncology Clinical Practice
Guidelines has a strong basis which can be outlined in several
issues: (i) the awareness of the toxicity of anthracyclines and
newer targeted agents and the planning of the optimal
treatment regimens that reduce cardiotoxicity without
compromising anticancer efﬁcacy; (ii) the detection of
potential cardiovascular (CV) effects needs to be an integral
part of treatment when potential cardiotoxic agents are used.
This begins with careful clinical assessment, paying attention
to subtle signs and symptoms such as minor impairment of
exercise capacity and a resting tachycardia; (iii) the prevention
of CV side-effects is a major issue. A careful CV work-up
should be undertaken before the initiation of chemotherapy
known to be associated with signiﬁcant cardiotoxicity. Strict
attention should be paid to patient comorbidities, especially
coronary artery disease and hypertension, in those patients
receiving multitargeted agents, and these comorbidities should
be robustly managed before and during therapy; (iv) the
identiﬁcation of areas of uncertainties related to (a) the
heterogeneity of the treated population in clinical trials; (b) the
fragmentation and limitation of prospective on long-term
survival data, treatment strategies and monitoring and (c) the
absence of information on elderly patients.
The purpose of these guidelines is to summarize the current
state of knowledge regarding CV complications, such as left
ventricular (LV) dysfunction (LVD), myocardial ischemia,
hypertension and QTc prolongation, associated with
commonly used anticancer drugs and radiotherapy (RT).
Following this assessment, the multidisciplinary board
provided recommendations on: (a) CV risk assessment and
prevention in cancer patients; (b) optimal screening and
monitoring of cardiac function during cancer treatment
(considering costs, feasibility and outcomes); (c) active
management of pre-existing cardiac disease to promote the
most effective cancer therapy; (d) active management of
chemotherapy, targeted agents or RT-induced cardiac toxicity.
These guidelines summarize the deliberations of a cross-
disciplinary working group, but do not bring together
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stakeholders involved in basic, translational and
pharmaceutical science.
nonreversible damage and reversible dysfunction
The use of many targeted agents, such as signaling inhibitors,
induces a cardiac dysfunction that resolves for most patients
over time. Suter and Ewer [1] proposed a system to identify
drugs that have the potential to cause irreversible damage
(Type I) versus drugs that predominantly induce reversible
dysfunction (Type II). This classiﬁcation system does have
limitations; for example, trastuzumab, a Type II drug, can
trigger irreversible cardiac damage in patients with severe
preexisting cardiac disease or potentiate anthracycline Type I
cardiotoxicity. In Type I cardiotoxicity, usually
pathophysiology is related to cell loss, and in Type II cellular
dysfunction (mitochondrial and protein alterations) underlies
the reversible damage. While nonreversible damage can induce
progressive CV disease, a reversible dysfunction is usually
temporary, with no injury marker release and will be recovered
with normalization of CV function. This is a seminal concept
that can impact ‘go no go’ decisions in the case of LVD induced
by targeted agents and that identiﬁes Type I (such as
anthracyclines) and type II (such as trastuzumab) agents.
LV dysfunction
One of the most common manifestations of cardiotoxicity
associated with exposure to anticancer therapies is the
development of LVD and overt heart failure (HF). The
deﬁnition of LVD has been proposed by the Cardiac Review
and Evaluation Committee supervising trastuzumab clinical
trials [2]. According to this deﬁnition, LVD is characterized by
a ‘(1) decrease in cardiac LV ejection fraction (LVEF) that was
either global or more severe in the septum; (2) symptoms of
congestive heart failure (CHF); (3) associated signs of CHF,
including but not limited to S3 gallop, tachycardia, or both;
and (4) decline in LVEF of at least 5% to less than 55% with
accompanying signs or symptoms of CHF, or a decline in
LVEF of at least 10% to below 55% without accompanying
signs or symptoms’. LVD and HF have been deﬁned by the
Common Terminology Criteria for Adverse Events (CTCAE)
for the purposes of uniform reporting [3]. The CTCAE criteria,
however, have changed over the years; and in the recently
updated version 4, HF and more specialized testing were
introduced (such as echocardiography and biomarker testing)
to provide a framework for a more sophisticated detection of
toxicity with newer chemotherapeutic and targeted agents.
Recent deﬁnitions have varied and include a greater change in
LVEF to below the lower limit of normal (LLN) or LVEF
<50%. As a consequence, at present, a consensus deﬁnition for
cardiotoxicity is still lacking.
anthracyclines and cytotoxics with cumulative dose-
related cardiotoxicity: Type I agents
Anthracyclines are a class of chemotherapeutics widely used in
the management of multiple malignancies, most prominently
in adjuvant therapy of breast cancer, as well as systemic
treatment of sarcomas, lymphomas and leukemia [4]. Since
most studies and registries have not speciﬁcally analyzed
anthracycline-induced cardiomyopathy (CMP) among the
several possible causes of chronic HF, formal estimates of the
worldwide prevalence of anthracycline cardiotoxicity are
lacking [5]. Anthracycline-induced cardiotoxicity has been
categorized into acute, early-onset chronic progressive and late-
onset chronic progressive. Acute cardiotoxicity occurs in <1%
of patients immediately after infusion of the anthracycline and
manifests as an acute, transient decline in myocardial
contractility, which is usually reversible. The early-onset
chronic progressive form occurs in 1.6%–2.1% of patients,
during therapy or within the ﬁrst year after treatment. Late-
onset chronic progressive anthracycline-induced cardiotoxicity
occurs at least 1 year after completion of therapy in 1.6%–5%
of patients. Early- and late-onset chronic progressive
cardiotoxicity typically present as dilated CMP in adults, which
can be progressive. Late-occurring cardiotoxicity may not
become clinically evident until 10–20 years after the ﬁrst dose
of cancer treatment. This classiﬁcation, however, dates back to
the early 1990s, and it is based on several, retrospective, small
studies, reporting the occurrence of symptoms of HF also
many years after the completion of anthracycline therapy in
childhood cancer survivors’ populations. Moreover, the clinical
usefulness and signiﬁcance of such a classiﬁcation is unclear,
particularly when the same classiﬁcation is applied to adult
populations, even if, at present, no prospective studies on long-
term cardiac effects of anthracycline chemotherapy are
available. Actually, the incidence and the timing of occurrence
of anthracycline-induced cardiotoxicity are, as yet, not well
deﬁned. Risk factors for anthracycline toxicity include
cumulative dose, intravenous bolus administration; higher
single doses; history of prior irradiation; the use of other
concomitant agents known to have cardiotoxicity including
cyclophosphamide, trastuzumab and paclitaxel; female gender;
underlying CV disease; age (young and elderly); increased
length of time since completion of chemotherapy; increase in
cardiac biomarkers, as troponins and natriuretic peptides,
during and after administration [6–9]. The risk of clinical
cardiotoxicity increases with a cumulative dose. Studies
evaluating cumulative probability of doxorubicin-induced HF
have found rates in the range of 3%–5% with 400 mg/m2,
7%–26% at 550 mg/m2 and 18%–48% at 700 mg/m2. The
recommended maximum lifetime cumulative dose for
doxorubicin is 400–550 mg/m2. After treatment with
anthracyclines, it is important to reassess cardiac function of
all patients to identify asymptomatic patients who are
experiencing increased cardiac damage; if LVEF has decreased
by either 15 percentage-points, or 10 percentage-points to a
value below 50 and a repeat assessment after 3 weeks conﬁrms
the ﬁnding; or if troponin or BNP are elevated, alternative
chemotherapeutic options should be discussed, as continuing
treatment with an anthracycline carries increased risk for
cardiotoxicity. Considerable variation exists in the
measurement of LVEF in that factors unrelated to the cancer
drug may have a substantial impact on cardiac function.
Treatment of anthracycline-induced cardiac dysfunction
warrants aggressive intervention with standard modalities
consistent with treatments for other forms of HF. No clear
consensus regarding the duration of the follow-up for
asymptomatic patients exists. A reasonable schedule might
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include a measurement of systolic function at 6 months after
the conclusion of treatment, annually for 2 or 3 years
thereafter, and then at 3- to 5-year intervals for life. Any CV
occurrence during the follow-up warrants more stringent
surveillance. High-risk patients, e.g. those with underlying CV
disease or those who have received >300 mg/m2 of doxorubicin
or equivalent, may be monitored more frequently, although
data to support an outcome advantage resulting from such
monitoring has not been reported.
alkylating agents
LVD has been associated with cyclophosphamide therapy in
7%–28% of patients. In addition, there are, as well, reports of
pericardial effusions and myopericarditis [10, 11]. The risk
of cardiotoxicity appears to be dose related (≥150 mg/kg and
1.5 g/m2/day). Another alkylating agent, ifosfamide, can induce
the onset of HF, with a dose–response trend (doses ≥12.5 g/
m2) [12].
inhibitors of microtubule polymerization
Paclitaxel and docetaxel are widely used in the treatment of
multiple malignancies. The incidence of HF associated with
taxanes according to retrospective analysis is relatively low. In
the Breast Cancer International Research Group trial 001, the
overall incidence of CHF (including that during follow-up) was
1.6% among patients treated with docetaxel–doxorubicin–
cyclophosphamide and 0.7% for those treated with 5-
ﬂourouracil–doxorubicin–cyclophosphamide (P = 0.09) [13].
monoclonal antibodies and targeted agents not
associated with cumulative dose-related cardiotoxicity:
type II agents
Monoclonal antibodies represent the paradigm of targeted
oncologic therapy and are widely used in the management of
multiple malignancies. In breast cancer, ∼15% of all tumors
overexpress the cell surface receptor HER2 and traditionally are
clinically deﬁned by aggressive behavior and worse prognosis.
Accordingly, the presence of the HER2 has served as an
optimal target for biologic therapies. The use of the humanized
monoclonal antibody trastuzumab (directed against the HER2
receptor) has revolutionized the treatment of HER2-positive
breast cancer, with landmark adjuvant phase III trials
demonstrating a 50% reduction in recurrence of disease and a
33% improvement in survival [14–18]. Rates of cardiac toxicity
reported in the adjuvant trials of trastuzumab have been
variable and reﬂect differences in trial design, chemotherapy
administration and deﬁnitions of cardiac events, as described
in Table 1.
Bevacizumab, a humanized monoclonal antibody directed
against vascular endothelial growth factor (VEGF), has
demonstrated substantial antitumor activity when combined
with chemotherapy, leading to regulatory approval for several
advanced solid tumors, including breast, lung, colorectal and
renal carcinomas. With greater use of bevacizumab, data are
emerging regarding potential cardiac toxicity. To date, the rates
of cardiac toxicity associated with bevacizumab therapy appear
to be relatively low. In the major phase 3 trials in metastatic
breast cancer, the reported rates of Common Terminology
Criteria for Adverse Events CTCAE grade 3/4 CHF were
0.8%–2.2% in mostly anthracycline-pretreated population [22].
Overall, clinical trial data to date do not suggest signiﬁcant
increases in cardiac toxicity during treatment with
bevacizumab, even in the setting of concurrent treatment with
other cardiotoxic agents. However, long-term monitoring of
patients who have completed bevacizumab therapy has not
been carried out; therefore, the safety of adjuvant bevacizumab
in the setting of cancer survivorship is unknown. The risk
factors for trastuzumab-associated cardiotoxicity identiﬁed
from clinical trials are: prior treatment with anthracycline
chemotherapy; a borderline LLN LVEF; prior treatment with
antihypertensive medication; older age; and a poorly
understood result found in one trial, a body mass index >25
kg/m2. In all adjuvant clinical trials, a common ﬁnding was
that cardiac dysfunction and HF occurred predominantly
during the trastuzumab treatment and was frequently
Table 1. Cardiac toxicity induced by trastuzumab
Trial Design Asymptomatic drop in LVEF
(≥10 percentage-points to
<55%)
Severe CHF/cardiac events
(NYHA class III/IV CHF or
death)
Discontinued
for cardiac
reasons
NSABP B31 [18] n = 2043 AC + TH +H versus AC + T 34% versus 17% 4.1% versus 0.8% 19% a
NCCTG N9831, n = 2766 [19] AC + TH +H versus AC + T +H
versus AC + T
5.8–10.4% versus 4.0–7.8%
versus 4.0–5.1%
3.3% versus 2.8% versus 0.3% n/aa
BCIRG 006, n = 3,222 [14] AC + T versus AC + TH +H
versus TCaHb
11% versus 19% versus 9% 0.7% versus 2.0% versus 0.4% n/a
HERA, n = 5,102 [20] Adj chemoc ≥H versus Adj
chemo alone
7.1% versus 2.2% 0.6% versus 0.06% 4.3%
FinHer, n = 232 [21] V or T + H versus V or Td
≥FEC × 3
3.5% versus 8.6% 0% versus 3.4% n/a
A, anthracycline; C, cyclophosphamide; T, taxane; H, trastuzumab; Ca, carboplatin; V, vinorelbine; F: 5-ﬂourouracil; E, epirubicin; n/a, information not
available.
a6.7% did not receive H after A due to unacceptable drops in LVEF.
bIncluded a nonanthracycline arm.
c96% of chemotherapy was A containing.
dNo prior anthracycline before H exposure; H exposure limited to 9 weeks.
Annals of Oncology clinical practice guidelines
Volume 23 | Supplement 7 | October 2012 doi:10.1093/annonc/mds293 | vii
reversible. Longer follow-up surveillance is needed in order to
better conﬁrm this observation. Optimal surveillance for
patients treated with Type II agents is not well established.
Patients who have received both anthracyclines and anti-HER2
agents who develop cardiac failure should be treated and
monitored as patients with an irreversible cardiac toxicity.
Those who develop cardiac dysfunction during or following
treatment with type II agents in the absence of anthracyclines
can be observed if they remain asymptomatic and LVEF
remains ≥40%. Persistently low or further declines in LVEF or
development of symptoms should trigger discussion of risk
and beneﬁt with the treating oncologist, as well as
consideration for pharmacologic cardiac treatment.
tyrosine kinase inhibitors and other targeted agents
Lapatinib, an oral receptor tyrosine kinase inhibitor (TKI) of
HER2 and EGFR, has an approved role in combination with
capecitabine chemotherapy in the treatment of patients with
trastuzumab-resistant breast cancer. Experience to date in a
relatively small studied population suggests relatively low rates
of symptomatic cardiac failure (1.4%), speciﬁcally in a
population with prior exposure to anthracycline and
trastuzumab [23]. Multiple small molecule TKIs of the VEGF
receptor (VEGFR) have been developed, including sunitinib
and sorafenib, with cross activity against other growth factor
receptors including platelet-derived growth factor (PDGF), c-
kit and BRAF. In contrast to bevacizumab, VEGFR antagonists
appear to have a more profound effect on cardiac function.
Initial reports of sunitinib in renal cell carcinoma suggested a
10% incidence of asymptomatic drop in LVEF to >10% LLN,
with full recovery when treatment was completed [24].
early detection of anticancer drug-induced LVD
At present, the most frequently used modality for detecting
cardiotoxicity is the periodic measurement of LVEF by using
either echocardiography or multigated acquisition scanning. To
date, however, there are no evidence-based guidelines for
cardiotoxicity monitoring during and after anticancer therapies
in adults, while guidelines in pediatric oncology are subject to
debate. Although several guidelines are available, none specify
how often, by what means, or how long cardiac function
should be monitored during and after cancer treatment [24].
Serial evaluation of LVEF is recommended for patients treated
with trastuzumab [25, 26]. However, the LVEF measurement is
a relatively insensitive tool for detecting cardiotoxicity at an
early stage. This is largely because no considerable change in
LVEF occurs until a critical amount of myocardial damage has
taken place, and only comes to the forefront after
compensatory mechanisms are exhausted. In addition, the
measurement of LVEF presents a number of challenges related
to image quality, assumption of LV geometry, load dependency
and expertise. Multiple-gated acquisition (MUGA) scan can
reduce interobserver variability with the disadvantages of
including the exposure to radioactivity and the limited
information than can be obtained on cardiac structure and
diastolic function. Magnetic resonance imaging (MRI) is
considered the gold standard for the evaluation of LV volumes,
mass and function. However, its lack of availability and high
cost limit its routine use. Novel ultrasound imaging techniques,
such as contrast echocardiography and real-time three-
dimensional (3D) echocardiography that allows for an
improvement in the accuracy of calculating LVEF, are under
investigation. Small studies examining tissue Doppler and
strain rate imaging appear to be promising in detecting early
subclinical changes in cardiac performance that anticipate a
decrease in conventional LVEF, even if long-term data on large
populations, conﬁrming the clinical relevance of such changes,
are not available yet [27].
In the last decade, a new approach, based on the use of cardiac
biomarkers, in particular troponins, has emerged, and has proven
to be a more sensitive and more speciﬁc tool for early, real-time
identiﬁcation, assessment and monitoring of anticancer drug-
induced cardiac injury [7, 8]. Strong data indicate that troponin
detects anticancer drug induced-cardiotoxicity in its earliest
phase, long before any reduction in LVEF has occurred. Its
evaluation during high-dose chemotherapy allows for the early
identiﬁcation of patients at risk of developing cardiac
dysfunction, the stratiﬁcation of risk of cardiac events after
chemotherapy and the opportunity for a preventive therapy in
selected high-risk patients [6–8]. In patients treated with
trastuzumab, troponin might help us to distinguish between
reversible and irreversible cardiac injury by identifying
myocardial cell necrosis [28]. The measurement of troponin
immediately before and immediately after each cycle of cancer
therapy seems to be effective enough, and is also transferable
from clinical research to real-world routine assessment.
treatment of anticancer drug-induced LVD
All patients with cancer who are treated with potentially
cardiotoxic therapy represent a high-risk group for the
development of HF. These patients have been excluded from
large randomized trials evaluating the effectiveness of
angiotensin-converting enzyme inhibitors (ACE-I) and beta-
blocking agents (BB). The use of ACE-I and BB may be highly
effective in this setting of patients. Recent ﬁndings reported in
a large population of anthracycline-induced CMP patients
demonstrated that the time elapsed from the end of
chemotherapy to the start of HF therapy (time-to-treatment),
with ACE-I and, when tolerated, with BB, is a crucial variable
for recovery of cardiac dysfunction [29, 30]. Indeed, the
likelihood of obtaining a complete LVEF recovery is higher in
patients in whom treatment is initiated within 2 months from
the end of chemotherapy. Although promising data have been
published, convincing evidence from large randomized and
prospective trials is still needed. Treatment of trastuzumab-
related cardiotoxicity (TIC) is a more controversial issue.
Despite new, updated guidelines for monitoring patients
receiving adjuvant trastuzumab being periodically published,
they are speciﬁcally focused on the continuation/withdrawal/
resuming of trastuzumab therapy. No evidence-based
recommendations for the treatment of patients developing
cardiac dysfunction after trastuzumab therapy have been
proposed. The evidence that support the use of ACE-I and BB
in this setting is limited to case series. Despite evidence, the
potential efﬁcacy of ACE-I and BB in improving LVEF in
patients receiving trastuzumab remains uncertain.
clinical practice guidelines Annals of Oncology
vii | Curigliano et al. Volume 23 | Supplement 7 | October 2012
prevention of anticancer drug-induced LVD
According to the American College of Cardiology and
American Heart Association guidelines, patients receiving
chemotherapy may be considered a Stage A HF group, namely
those with an increased risk of developing cardiac dysfunction
[24]. Carvedilol may prevent cardiac damage induced by
doxorubicin due to its antioxidant activity. The effect of
carvedilol was conﬁrmed in a randomized study in which
prophylactic use of carvedilol in a small population of patients
treated with anthracycline prevented LVD and reduced
mortality [31]. Nakamae et al. [32] have demonstrated that
valsartan, an angiotensin receptor blocker (ARB), given
concurrently to anthracycline-containing regimens, prevents
cardiac damage. Dexrazoxane, an iron-chelating agent,
Figure 1. Algorithm for the management of cardiotoxicity in patients receiving anthracyclines.
Figure 2. Algorithm for continuation and discontinuation of trastuzumab based on LVEF assessments.
Annals of Oncology clinical practice guidelines
Volume 23 | Supplement 7 | October 2012 doi:10.1093/annonc/mds293 | vii
signiﬁcantly reduces anthracycline-related cardiotoxicity in
adults with different solid tumors and in children with acute
lymphoblastic leukemia and Ewing’s sarcoma [33].
Dexrazoxane is not routinely used in clinical practice and it is
recommended as a cardioprotectant by the American Society
of Clinical Oncology only for patients with metastatic breast
cancer who have already received more than 300 mg/m2 of
doxorubicin.
Figure 1 reports the algorithm for the management of
cardiotoxicity in patients receiving anthracyclines. Figure 2
reports the algorithm for continuation and discontinuation of
trastuzumab based on LVEF assessments. Table 2 reports
recommendations for CV evaluation before anticancer
treatment. Table 3 reports recommendations for CV
monitoring during and after anticancer treatment with
potential cardiotoxicity (including anti-HER2 agents). Table 4
reports on treatment of LVD induced by anticancer treatment
(including anti-HER2 agents).
management of trastuzumab cardiotoxicity
Management of trastuzumab-related cardiotoxicity has two
distinct aspects: withdrawal of trastuzumab therapy and
treatment of cardiac dysfunction.
The ‘stopping/restarting’ rules used in the adjuvant trials
were effective and are recommended, with some modiﬁcations
regarding recommendations for a cardiology consult or
treatment of cardiac dysfunction (or both) when appropriate.
Symptomatic LVD must be treated with HF treatment:
• All patients with HF and an LVEF <40% should be
treated with an ACE-I in combination with a BB unless
a speciﬁc contraindication exists [I, A].
Table 2. CV evaluation before anticancer treatment with potential nonreversible (Type I) or reversible (type II) cardiotoxicity
Guideline statements Level of
evidence
Grade of
recommendation
Baseline evaluation
Patients undergoing chemotherapy should have careful clinical evaluation and assessment of CV risk factors and
comorbidities. Strict attention should be paid to patient comorbidities, especially coronary artery disease and
hypertension, in those patients receiving multitargeted agents, and these comorbidities should be robustly
managed before and during therapy
I A
Patients should be considered at risk for cardiac toxicity in case they have history of exposure to any of the
following cumulative doses of anthracyclines as speciﬁed below.
• Doxorubicin >500 mg/m2
• Liposomal doxorubicin >900 mg/m2
• Epirubicin >720 mg/m2
• Mitoxantrone >120 mg/m2
• Idarubicin >90 mg/m2
I A
LVEF assessment is mandatory for basal evaluation cardiac function before potential cardiotoxic cancer treatment I A
A standard 12-lead ECG should be recorded. The QT time should be corrected for heart rate (QTc) with Bazett’s
formula (QTc = QT/√RR)
I B
Echocardiography is the standard procedure for basal assessment of cardiac structure, performance and
hemodynamics. Multiple gated acquisition (MUGA) scan can reduce interobserver variability with the
disadvantages of including the exposure to radioactivity and the limited information than can be obtained on
cardiac structure and diastolic function. Magnetic resonance imaging (MRI) is another method used to evaluate
myocardial function. Its spatial resolution is higher than that of echocardiography, but its temporal resolution is
lower.
I A
Assessment by ultrasound should obtain 2D or 3D images in the left ventricular parasternal long- and short-axis
views and in the apical four- and two-chamber long-axis views. For the analysis of diastolic function, the
following parameters should be measured: the ratio of early peak ﬂow velocity to atrial peak ﬂow velocity (E/A
ratio; normal value >1), the deceleration time of the early peak ﬂow (DT; normal value <220 ms) and the
isovolumic relaxation time (IVRT; normal value <100 ms). Left ventricular end-diastolic diameter (normal
value, 47 ± 4 mm) should be measured to test for ventricular dilatation
I A
Cardiac biomarkers such as the troponins and brain natriuretic peptides (BNP), and neutrophil glucosaminidase-
associated lipocalin as a marker of renal injury, may be expected to be elevated with signiﬁcant cardiotoxicity.
Although it is not yet established whether their routine monitoring is useful in predicting cardiotoxicity, and
this needs to be examined in prospective studies, there is a strong case to incorporate their use in the clinical
trial setting
III B
Treatment optimization of pre-existent cardiopathies: BB and ACE inhibitors where appropriate, maximize
medical therapy for patients with coronary artery disease, coronary revascularization if clinically appropriate
I A
To minimize cardiotoxicity, the use of liposome-encapsulated doxorubicin and the use of an appropriate
cardioprotectant regimen (as dexrazoxane, BB, ACE-inhibitors, AT1-antagonists) should be considered and
planned in all patients at high risk of cardiotoxicity
III B
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• Some members of the panel also felt that, to prevent
further degradation of LVEF or the development of
clinical HF, an ACE-I should be considered if the
patient’s LVEF is between 40% and 50%.
Asymptomatic LVD should be treated:
• ACE-Is should be used in all asymptomatic patients with
LVD and an ejection fraction <40% [I, A for ejection
fraction <35%; I, B for ejection fraction 35%–40%].
• Also, an ACE-I should be considered if LVEF is <50%.
• BB should be considered in all patients with
asymptomatic LVD and an LVEF <40% [if prior
myocardial infarction I, B; if no myocardial infarction
II, C].
cardiac ischemia
Although cardiac ischemia related to chemotherapy
administration is an unusual occurrence, an increased risk of
acute coronary syndrome has been associated with
administration of cytotoxic and targeted agents for cancer
treatment.
antimetabolites. The incidence of cardiac events associated
with 5-FU varies in the literature ranging anywhere from 1% to
68% [34]. Cardiac toxicity typically occurs with early onset
(within 2–5 days of starting therapy). Ischemic
electrocardiogram (ECG) changes have been reported in up to
68% of patients, although in the majority evidence of cardiac
Table 3. CV monitoring during and after anticancer treatment with potential non-reversible (Type I) or reversible (type II) cardiotoxicity
Guideline statements Level of
evidence
Grade of
recommendation
Cardiac monitoring
Patients receiving anthracyclines and/or trastuzumab in the adjuvant setting should perform serial monitoring of
cardiac function at baseline, 3, 6 and 9 months during treatment, and then at 12 and 18 months after the
initiation of treatment. Monitoring should be repeated during or following treatment as clinically indicated.
Limited data are available for elderly patients: increased vigilance is recommended for patients ≥60 years old
I A
Patients treated for metastatic disease: LVEF should be monitored at baseline and then infrequently in the absence
of symptoms
II A
Troponin I or BNP concentrations seem to identify patients at risk of cardiotoxicity, speciﬁcally in case of
administration of type I agents (such as anthracyclines). Performing baseline assessment of biomarker
concentrations and periodic measurements during therapy (every each cycle) may identify patients who need
further cardiac assessment
III B
Assessment of cardiac function is recommended 4 and 10 years after anthracycline therapy in patients who were
treated at <15 years of age, or even at age >15 years but with cumulative dose of doxorubicin of >240 mg/m2 or
epirubicin >360 mg/m2
II B
LVEF reduction of ≥15% from baseline with normal function (LFEV≥ 50%) is an indication to continue
anthracyclines and/or trastuzumab. LVEF decline to <50% during anthracyclines containing regimens
necessitate reassessment after 3 weeks. If conﬁrmed, hold chemotherapy, consider therapy for LVD and further
frequent clinical and echocardiographic checks. In case of LVEF decline to <40% stop chemotherapy, discuss
alternatives and treat LVD
II B
LVEF decline to <50% during trastuzumab therapy (post-anthracyclines) necessitate reassessment after 3 weeks. If
conﬁrmed, continue trastuzumab and consider therapy for LVD and further frequent clinical and
echocardiographic checks. In case of LVEF decline to <40% stop trastuzumab and treat LVD
Aggressive medical treatment of those patients, even asymptomatic, who show LVD at DEcho after anthracycline
therapy is mandatory, especially if the neoplasia could have a long-term survival; it consists of ACE inhibitors
and b-blockers and the earlier HF therapy is begun (within 2 months from the end of anthracycline therapy),
the better the therapeutic response
Table 4. Treatment of LVD induced by anticancer treatment with non-reversible (Type I) or reversible (Type II) cardiotoxicity
Guideline statements Level of
evidence
Grade of
recommendation
Treatment
In patients with subclinical cardiotoxicity induced by Type I agents, identiﬁed also by increase in cardiac troponin,
a treatment with ACE inhibitors (enalapril) may prevent LVEF reduction and associated cardiac events
II A
Patients who develop cardiac dysfunction during or following treatment with Type II agents (trastuzumab) in the
absence of anthracyclines can be observed if they remain asymptomatic and LVEF remains ≥40%. Persistently
low or further declines in LVEF or development of symptoms should trigger discussion of risk and beneﬁt with
the treating oncologist, as well as consideration for pharmacologic cardiac treatment
Patients who develop LVD should be treated with standard guideline-based HF therapy just as any other HF
patient
II A
Annals of Oncology clinical practice guidelines
Volume 23 | Supplement 7 | October 2012 doi:10.1093/annonc/mds293 | vii
myocyte damage including elevation in serum cardiac markers
is lacking [34]. Coronary artery thrombosis, arteritis and
vasospasm secondary to drug exposure have been proposed as
the most likely underlying mechanisms.
inhibitors of microtubule polymerization. Paclitaxel
administration has been associated with cases of myocardial
ischemia and infarction. A retrospective study reviewed cardiac
events in four clinical trials, and reported manifestations of
cardiac ischemia in 5% of patients [35].
endocrine agents. Aromatase inhibitors (AIs) are an
established component of the treatment of postmenopausal
hormone receptor-positive breast cancer. Cardiac events,
including myocardial infarction and cardiac failure, have been
reported at low frequency in the major adjuvant trials
comparing the use of AIs to a control arm of 5 years of
tamoxifen. A meta-analysis of over 19 000 participants in
adjuvant studies suggests a relative risk of 1.31 (95% CI 1.01–
1.60, P = 0.007) for a cardiac adverse event associated with
exposure to an AI compared with tamoxifen, although the
absolute risk remains low, ∼0.5% [36]. Differential changes in
lipid proﬁle have been proposed as an etiology for these
observations; however, a strong signal linking AIs and relevant
changes in lipid levels are lacking. The long-term clinical
signiﬁcance of these clinical observations remains unclear.
targeted agents. Whether novel molecular therapies increase
the risk of cardiac ischemia is not clear. In an evaluation of the
VEGF receptor antagonist sunitinib, 18% of 68 patients studied
were noted to have modest increases in cardiac troponins,
possibly serving as a biomarker of myocyte damage [37].
clinical recommendations
Ischemic events following or during antimetabolites or
paclitaxel infusion
Baseline ECG evaluation is recommended [III/IV, A]
Frequent vital sign monitoring is recommended during
chemotherapeutic agent infusion, particularly with 5-FU or
paclitaxel [III/IV, A]. Monitoring of BNB and troponin I
should be recommended in patients with anamnesis of cardiac
ischemia [III/IV, C].
A collaborative decision should then be made as to whether
more advanced cardiac testing (e.g. stress testing and coronary
angiography) is needed and whether the beneﬁts of resuming
therapy with aggressive supportive care outweigh the risk.
hypertension
Multiple investigative and clinical observations have
demonstrated hypertension to be a common class effect
resulting from treatment with VEGF inhibitors. The rates of
substantial hypertension appear to depend on the
antiangiogenic agent used, the tumor type and patient-related
factors including age and comorbidity. Angiogenesis inhibitor-
related hypertension is typically manageable with early
initiation of pharmacologic therapy to reach accepted blood
pressure (BP) targets. Preferred antihypertensive agents for
angiogenesis inhibitor-associated hypertension include ACE-I
and dihydropyridine calcium channel blockers, although there
are minimal data to suggest superiority of a single class of
agents. Early and aggressive initiation of antihypertensive
therapy appears to help maintain treatment schedule and
reduce the risk of substantial complications, including
malignant hypertension and reversible posterior
leukencephalopathy.
The exact mechanism underlying the hypertension
associated with angiogenesis inhibitors is not well deﬁned.
However, several theories have been proposed, including an
imbalance in neurohumoral factors, the development of
vascular rarefaction or an alteration in vascular nitric oxide
balance [38, 39]. The alternative hypothesis of vascular
rarefaction, the process of reduced microvascular density, has
been proposed to result in hypertension through increases in
systemic vascular resistance. Prospective evaluation of patients
receiving anti-VEGF agents has demonstrated reductions in
capillary microdensity and alterations in capillary endothelial
function in the setting of documented hypertension support
this event as a contributing factor [40, 41].
clinical recommendations for assessment and
management of patients candidate to
antiangiogenic agent inducing hypertension
Individuals should be considered at risk in case of: systolic BP
≥160 mmHg or diastolic BP ≥100 mmHg; diabetes mellitus;
established CV disease including any history of ischemic
stroke, cerebral hemorrhage or transient ischemic attack;
myocardial infarction, angina, coronary revascularization, or
HF; peripheral artery disease; subclinical organ damage
previously documented by ECG or echocardiogram revealing
left ventricular hypertrophy; cigarette smoking; dyslipidemia.
Repeated BP measurements are recommended.
Aggressive management of BP elevations is recommended to
prevent clinically limiting complications.
There are no evidence-based guidelines for follow-up
echocardiograms in asymptomatic patients receiving
antiangiogenic agents. Although some LVEF-based dose
modiﬁcation algorithms have been used in clinical trials that
called for periodic echocardiogram/MUGA assessments, at the
time of writing, there are no data on which to base general
recommendations for antiangiogenic agents dose adjustment.
QT prolongation
Prolongation of the QT interval can lead to life-threatening
cardiac arrhythmias, including ‘torsade de pointes’ (TdP).
Although prolongation of the QT interval is not the best
predictor of proarrhythmic risk, it represents the principal
clinical surrogate marker by which to evaluate the arrhythmic
risk of a drug, and it has led to withdrawal of several
anticancer drugs from the market. Although drugs leading to
prolonged QT may possess substantial risks of serious adverse
events, the clinical beneﬁt of therapy in the oncologic setting,
including the possibility of cure for a cancer patient, may
outweigh the potential risks of QTc prolongation, even when
the prolongation is signiﬁcant [42].
arsenic trioxide. Arsenic trioxide (ATO) presents an
interesting example of successful risk management, supporting
a decision for a patient to accept, or a physician to administer,
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an anticancer drug with established liabilities of QTc
prolongation. Although this drug is known to provoke QTc
prolongation and TdP, it is also uniquely effective in an
otherwise fatal disease, relapsed acute promyelocytic leukemia
[43]. Therefore, until alternative therapy becomes available,
ATO remains a drug of choice, despite its potential for causing
arrhythmia. In patients receiving multiple courses, QTc
intervals may return to pre-treatment levels before the second
course, implying that serial ATO administration does not
permanently prolong the QTc interval; however, documented
episodes of TdP have been observed beyond the ﬁrst month of
treatment, presumably due to drug accumulation in cardiac
tissue [43].
clinical recommendation for patients receiving
drugs prolonging QTc interval
Patients with a history of QT interval prolongation, patients
who are taking antiarrhythmics, or patients with relevant CV
disease, bradycardia, thyroid dysfunction or electrolyte
disturbances should be screened and monitored. Periodic
monitoring with on-treatment ECGs and electrolytes should be
considered.
cardiac toxicity induced by RT
A considerable amount of literature supports evidence of
radiation-related heart injury after RT to the chest. The most
appropriate groups of patients where radiation-associated
cardiac injuries are of clinical importance are those with
curable malignancies irradiated at a relatively younger age, so
there is enough time to develop clinically signiﬁcant late
cardiac injury. Such malignancies are mainly Hodgkin’s
lymphoma and early-stage breast cancer, while there is an
increasing number of lung and esophageal cancer patients with
long-term controlled disease who could develop post-RT
cardiac sequelae. Radiation-associated CV toxicity may be
progressive. Complex, combined disease of heart coronary
arteries, valves, myocardium and conduction system as well as
diastolic dysfunction may be seen [44, 45]. Estimates of relative
risk of fatal CV events after mediastinal irradiation for
Hodgkin’s disease ranges between 2 and 7 and after irradiation
for left-sided breast cancer from 1.0 to 2.2.
Risk factors for radiation-associated heart damage include:
• dose >30–35 Gy
• dose per fraction >2 Gy
• large volume of irradiated heart
• younger age at exposure
• longer time since exposure
• use of cytotoxic chemotherapy
• endocrine therapy or trastuzumab
• presence of other risk factors such as diabetes, hypertension,
dyslipidaemias, obesity, smoking etc.
evidence from breast cancer patients
In the last update of the Early Breast Cancer Trialists’
Collaborative Group (EBCTCG) meta-analysis on locoregional
RT, comparison of CV mortality between patients treated with
and without RT has shown a statistically signiﬁcant relative
risk of 1.27. A similar latent time was estimated in an overview
of trials started before 1975.
In a Swedish study that included 55 000 patients, a mortality
ratio of all CV disease for left versus right side in a period of
>10 years after treatment was 1.10 [95% conﬁdence interval
(CI) 1.03–1.18] for all CV diseases and 1.13 (95% CI 1.03–
1.25) for deaths from ischemic disease. Other studies conﬁrm
those results.
evidence from Hodgkin’s lymphoma patients
Mediastinal RT can cause a variety of CV complications such
as pericarditis, myocardial ﬁbrosis, coronary artery disease,
valvular abnormalities and conduction disturbances [46].
Restrictive CMP, valvular defects and conduction defects,
persistent tachycardia and blunted hemodynamic responses to
exercise are usually diagnosed. Nevertheless, myocardial
infarction is the major cause of higher long-term mortality in
survivors of Hodgkin’s disease. It is very important to note that
death due to cardiac causes is estimated to be responsible for
about one-quarter of the mortality from reasons other than
Hodgkin’s disease itself, which equals 2%–5% of overall
mortality in those with Hodgkin’s disease.
cardiac structures affected by radiation
Injury of the various structures and tissues in the heart can
cause a spectrum of radiation-induced CV diseases. Arteritis of
the endothelium of coronary arteries can cause premature
coronary artery disease and atherosclerosis mainly in left
anterior descending and right coronary artery. The time of
appearance is 10–15 years after RT.
• Acute pericarditis and symptomatic (hemodynamic
compromise with constriction or tamponade) or
asymptomatic chronic pericardial effusion appears usually 6–
12 months following RT.
• Myocarditis and CHF due to nonspeciﬁc diffuse interstitial
ﬁbrosis.
• Valvular stenosis and regurgitation mainly of mitral and
aortic valves.
• Fibrosis of the conduction system and disturbed heart rate
and complete or incomplete heart block.
• Some indirect implications on the heart may result from
irradiation of adjacent structures. Lung and mediastinal
ﬁbrosis may result in respiratory insufﬁciency, pneumonic
hypertension and may complicate any potential heart
surgery. Hypothyroidism may affect the lipid proﬁle and CV
function. Mediastinal venous and lymph vessel obstruction
may cause pericardial effusion or chylothorax.
Radiation tolerance doses for the above late-effects have been
estimated to be between 30 and 40 Gy.
recommendations to reduce cardiac toxicity in
patients treated by RT
There is some evidence that newer irradiation techniques seem
to decrease the risk of RT-induced cardiac disease, but a longer
follow-up time is needed to conﬁrm it. Modern RT techniques
include 3D treatment planning with dose volume histogram for
Annals of Oncology clinical practice guidelines
Volume 23 | Supplement 7 | October 2012 doi:10.1093/annonc/mds293 | vii
accurate heart volume and dose calculation. Linear accelerator
photons and multiple ﬁeld conformal or intensity-modulated
RT (IMRT) are desirable for chest irradiation.
Normal tissue complication probability (NTCP) is a method
of reporting radiation dosing in RT, by taking into account the
dose and the volume of normal tissues that receive the
corresponding dose [47]. The NTCP model estimates predict
that a V25Gy <10% (i.e. a dose of 25 Gy (in 2 Gy per fraction) in
<10% of the whole volume of heart) will be associated with 1%–
2% probability of cardiac mortality within 15 years after RT.
For (left) breast/chest wall RT, 6 MV or occasionally higher
energy photons (for large breasts) from a linear accelerator
should be used. The introduction of cardiac-sparing lead block
during standard simulator planning will result in cardiac
irradiation being at least partially avoided in many patients.
The use of a four-ﬁeld IMRT technique can offer better
sparing than the partial shielding technique as the maximum
heart depth is increased. The IMRT plans also showed
improved dose homogeneity within the Planning Target
Volume (PTV) but may be associated with increased
irradiation of the contralateral breast.
It has been proposed that maximum heart distance (MHD),
i.e. the maximal distance between anterior cardiac contour and
posterior tangential ﬁeld edges as seen on the beam’s eye view,
is a reliable predictor of the mean heart dose in left-tangential
breast or chest wall irradiation, and may be useful in centers
where 3D cardiac dose assessment is not routinely available. A
strong linear correlation was found between the MHD and the
mean heart dose: for every 1-cm increase in MHD, the mean
heart dose increased by 2.9% on average (95% CI 2.5–3.3).
Electron beams can be used for the treatment of superﬁcial
structures such as in the internal mammary lymph nodes or
the boost dose on the breast after tumorectomy, in the
treatment of breast cancer.
For mediastinal RT, high-energy photons from a linear
accelerator should be used to treat patients with equal weighting
of anterior and posterior portals (instead of anterior weighting),
all ﬁelds should be treated on each RT fraction, use of a
subcarinal block after a dose of 30 Gy and use of shrinking-ﬁeld
technique are the most important parameters to minimize heart
exposure. As Adams et al. has stated, although permanent
complications tend to occur less frequently under a total dose of
40 Gy, it is not a good idea to systematically limit treatment,
which may be inadequate to control the neoplastic disease.
treatment of RT-related heart complications
Radiation-induced heart diseases are treated as nonradiation-
related ones, but with special attention to the changes radiation
causes to the heart and other structures of the chest.
monitoring of cardiac function after chest RT
Patients at high risk for RT-induced complications are those
treated as children or young adults for Hodgkin’s lymphomas
with a mediastinal/heart dose of >30 Gy, mainly with what are
called outdated RT techniques (see above). Those patients
should be informed and followed up closely [III,A]. Radiation-
related heart toxicity is extremely rare during RT.
Breast cancer patients treated by cytotoxic chemotherapy or
monoclonal antibodies should be monitored. Patients treated
by postoperative breast RT (with or without adjuvant
endocrine treatment) are not regularly monitored for cardiac
problems although RT should be considered as a risk factor
when heart disease is diagnosed in those patients [III, B].
Data to support deﬁnitive recommendations on various tests
and their frequency do not exist. However, RT-induced risk is
ongoing and requires long-term follow-up. Screening and
monitoring of heart function is identical to the standard tests
and procedures cardiologists use for other patients, and
consequently the follow-up protocols are based on
departmental or personal experience and on each patient’s
needs and clinical picture. There is therefore a need for both
oncologists and cardiologists to be aware of the risks and
underlying pathophysiology of RT-related heart complications.
Apart from clinical examination and medical history, tests
usually requested depend on the studied abnormality.
• Coronary artery disease: lipid proﬁle, exercise stress test,
radionuclide, angiography, echocardiogram, ECG.
• Pericarditis: ECG, chest X-ray and echocardiogram.
• CMP: ECG, echocardiogram, and radioisotopic angiography.
• Arrythmias: ECG and 24-h ECG.
• Valvular disease: echocardiogram, cardiac catheterization.
conclusions
Within the oncologic toolbox are both traditional and novel
anticancer agents with the potential to induce cardiac toxicity.
Oncologists thus have had to develop the ability to identify and
manage complicated cardiac risks in clinical investigations and
in general practice. Many highly effective agents in
contemporary oncology, including anthracyclines and
trastuzumab, are associated with well-described risks of short-
and long-term cardiac events. As these agents are often used
with curative intent, maximizing the beneﬁts while reducing
cardiac risks has become a priority in oncologic management,
as well as monitoring for late-term toxicity. Additionally, given
the inﬂux of novel biologic therapies designed to fulﬁll unmet
medical needs, efforts are needed to promote strategies for risk
detection and management to avoid dangerous toxicities which
may impede development of and patient access to new agents.
In principle, the risk–beneﬁt ratio for an agent must be
interpreted in the context of the nature and severity of the
disease, and restrictive approaches have the potential to delay
or prevent access to innovative treatment. More research is
needed to assess and manage the CV safety of patients treated
with anticancer agents, beginning with a dynamic partnership
between oncologists and cardiologists, and the development of
a new generation of ‘cardio-oncologic’ investigators. A
thoughtful risk management plan generated by an organized
collaboration between oncologists, cardiologists and regulatory
agencies can support developmental programs essential for
anticancer agents with cardiac safety concerns.
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